in vivo News and Research

RSS

PE, CT appear to reduce PTSD symptoms in patients with recent traumatic event

Prolonged exposure therapy, cognitive therapy, and delayed prolonged exposure therapy, appear to reduce posttraumatic stress disorder symptoms in patients who have experienced a recent traumatic event, according to a report published Online First by Archives of General Psychiatry, one of the JAMA/Archives journals.

4 Oct 2011

MRI-based technique allows researchers to follow neural stem cells in vivo

Carnegie Mellon University biologists have developed an MRI-based technique that allows researchers to non-invasively follow neural stem cells in vivo.

30 Sep 2011

New insights into actions of NSAIDs

Ibuprofen, naproxen, and related non-steroidal anti-inflammatory drugs (NSAIDs) - the subjects of years of study - still have some secrets to reveal about how they work.

26 Sep 2011

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Patrys Limited has announced that its lead anti-cancer antibody PAT-SM6 has shown significant activity in preclinical studies of multiple myeloma.

26 Sep 2011

National HIV/AIDS Strategy meeting to be held at UAB

The White House Office of National AIDS Policy is holding a series of National HIV/AIDS Strategy Implementation Dialogues across the country to examine critical issues and encourage action and collaboration at the state and local levels. The first meeting, focusing on incorporating prevention and care research into HIV programs, is being held at the University of Alabama at Birmingham on Tuesday, Sept. 27, 2011.

23 Sep 2011

Researchers analyse effects of BPA in an in-vitro culture of ovaries

Researchers at Universitat Aut-noma de Barcelona, in collaboration with the Vall d'Hebron Hospital Fetal Tissue Bank, the Department of Gynaecology and the Research Unit of Paediatric Endocrinology, analysed the effects of Bisphenol A (BPA), a polymer widely used to manufacture plastics, in an in vitro culture of ovaries.

22 Sep 2011

Positive data from InVivo's biomaterial scaffold implant preclinical study on acute SCI

InVivo Therapeutics Holdings Corp., a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that in a rodent contusion model of SCI the Company's proprietary biopolymer scaffold showed positive preliminary data that indicate a therapeutic effect.

21 Sep 2011

Clinical trial to evaluate TAU's stem cell technology for ALS

The ability to produce neuroprotectors, proteins that protect the human brain against neurodegenerative disorders such as Parkinson's and ALS, is the holy grail of brain research. A technology developed at Tel Aviv University does just that, and it's now out of the lab and in hospitals to begin clinical trials with patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

21 Sep 2011

Potential new treatment for fragile X syndrome

Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.

16 Sep 2011

Polyplus-transfection appoints ten additional biologists and chemists to support multiple pre-clinical studies

Polyplus-transfection SA, which specializes in the development of innovative solutions for the delivery of nucleic acids in research and therapeutics, today celebrates ten years of continuous growth.

15 Sep 2011

DiscoveryBioMed receives NIDDK grant for Cystic Fibrosis Corrector Ligand Drug Discovery program

DiscoveryBioMed, Inc. (DBM), a human cell-based drug discovery company, learned recently that its Cystic Fibrosis Corrector Ligand (CFCL) Drug Discovery program will be funded by the NIH. The two-year award will focus on validation and prioritization of several lead CFCL chemical classes, drugs that correct the most common cystic fibrosis (CF) disease-causing mutation.

14 Sep 2011

Tensha raises $15 million in Series A financing to advance bromodomains for cancer

Tensha Therapeutics announced today that it has raised $15 million in a Series A financing to advance the development of small molecule bromodomain inhibitors for the treatment of cancer and other conditions by regulating the transcription of disease-associated genes.

12 Sep 2011

Mayo Clinic develops genome-based immunization strategy against feline AIDS

Mayo Clinic researchers have developed a genome-based immunization strategy to fight feline AIDS and illuminate ways to combat human HIV/AIDS and other diseases. The goal is to create cats with intrinsic immunity to the feline AIDS virus. The findings -- called fascinating and landmark by one reviewer -- appear in the current online issue of Nature Methods.

12 Sep 2011

InteRNA, Silence partner to develop novel microRNA therapeutics for cancer

Silence Therapeutics plc, a leading global RNA interference (RNAi) therapeutics company, and InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA-based therapeutics for cancer, today announce that they have entered into an agreement to develop novel microRNA therapeutics for the treatment of cancer.

12 Sep 2011

Aura's NanoSmart platform can enable earlier detection, treatment of cancers

Aura Biosciences, Inc., a biotech company focused on the development of nano-enabled drug delivery systems, has completed several pre-clinical research programs. The resulting data suggest that Aura's NanoSmart platform can enable earlier detection of cancers and distant metastases; and then provide precisely targeted treatment of those cancers.

9 Sep 2011

ATA announces five recipients of 2011 thyroid cancer research grants

The American Thyroid Association (ATA) announced the five recipients of its 2011 research grants, each of whom will receive up to $25,000 annually for up to two years. Three of the five recipients were awarded special ATA ThyCa grants for research projects that focus on thyroid cancer. These grants are funded by ThyCa: Thyroid Cancer Survivors, Inc.

8 Sep 2011

Cyclic proteins transport drugs faster

Biologists at the Technische Universität Darmstadt have discovered means for speeding the transport of the active ingredients of drugs into live cells that might allow drastically reducing drug dosages in the future.

8 Sep 2011

APS sponsors 7th International Symposium on Aldosterone and the ENaC/Degenerin Family of Ion Channels

The American Physiological Society is sponsoring the 7th International Symposium on Aldosterone and the ENaC/Degenerin Family of Ion Channels, being held September 18-22 at the Asilomar Conference Grounds in Pacific Grove, Calif. This scientific conference explores the connection between fluid balance in the body and hypertension, a growing global health concern.

8 Sep 2011

Researchers rethink fenretinide for prevention of oral cancer

Scientists on the cutting edge of biomedical research know that research is a process - a combination of successes and failures that inform the next step forward. However, for some researchers at The Ohio State University progress means taking a step back. Supported by the Ohio State University Center for Clinical and Translational Science (CCTS), these scientists are using failed and forgotten research to uncover future treatments for major health conditions as diverse as oral cancer and stroke.

7 Sep 2011

SWOG selects four cancer researchers for 2011 Young Investigator Training Course

SWOG has selected four talented, early-career researchers for its 2011 Young Investigator Training Course. These four will attend a three-day workshop September 19 - 21 in Seattle, Wash., for intensive training in how to design and conduct cancer clinical trials.

3 Sep 2011